July 10, 2019
Simulations Plus Reports Third Quarter FY2019 Financial Results
Record quarter as revenues grow 16%, 9MoFY19 revenues up 13% Board of Directors announces quarterly dividend of $0.06 per share…
pharmaceutical daily
Pharmaceuticals, Biotechnology and Life Sciences
July 10, 2019
Bipartisan Bill Will Strengthen Patent Rights and Protect U.S. Leadership in Biotechnology Innovation
Strong patent rights are essential to finance the revolution in biotechnology discoveries from the lab to the patient, farmer, and…
July 10, 2019
Walgreens Boots Alliance Increases Quarterly Dividend
DEERFIELD, Ill.–(BUSINESS WIRE)–Walgreens Boots Alliance, Inc. (Nasdaq: WBA) today announced that its board of directors has declared a quarterly dividend…
July 10, 2019
INSERTING AND REPLACING Altasciences Leads Research on Chemical Nerve Agent Therapeutic from Preclinical to Clinical Phase I
LAVAL, Québec–(BUSINESS WIRE)–#Altasciences–Insert in first paragraph, first sentence of release issued May 22, 2019, at 8:04 a.m. ET: New text.…
July 10, 2019
Frank Schestag, PhD, Joins Proteintech as Commercial Director in Europe
ROSEMONT, Ill.–(BUSINESS WIRE)–#Proteintech–Proteintech, the benchmark in antibodies and proteins, welcomes Frank Schestag, PhD, as Commercial Director. He will be providing…
July 10, 2019
Newron’s commercialization partner Zambon and Valeo Pharma announce the launch of Onstryv® (safinamide) for Parkinson’s disease in Canada
MILAN & MONTREAL–(BUSINESS WIRE)–$NWRN–Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5.XE), a biopharmaceutical company focused on the development of novel…
July 10, 2019
Taris bio tests its TAR-200 with Opdivo
Taris Bio has dosed the first patient in a test of its investigational product TAR-200 combined with Bristol-Myers Squibb’s Opdivo.
July 10, 2019
Biomarkc posts improvement in Phase 2 Study in Non Small Cell Lung Cancer
Biomarck Pharmaceuticals has improved the Overall Response Rate (ORR) in the BIO-11006/SOC group compared to standard of care alone at 3 months in the Phase 2 study in NSCLC, which compares standard of care alone, to SOC plus BIO-11006 in 60 patients with stage 4.
July 10, 2019
Dr. Reddy’s to release Q1 FY 20 results on July 29, 2019
Earnings call slated for July 29, 6:30 PM IST / 9:00 AM EDT HYDERABAD, India–(BUSINESS WIRE)–Dr. Reddy’s Laboratories Ltd. (BSE:…
July 10, 2019
Point-of-Care Diagnostics and Technologies Take Center Stage at Next Generation Dx Summit, August 20-22 in Washington, DC
800 Leaders Unite to Advance Rapid Diagnostics Opening New Frontiers in Precision Medicine WASHINGTON–(BUSINESS WIRE)–#Biomarkers–Responding to the growth of the…